SCHEMBL2932651

SCHEMBL2932651

CSc1nccc(-c2cc3c(NC(=O)OCc4ccccc4)n[nH]c3nc2-c2cccc(C(F)(F)F)c2)n1

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.40
MGLL Q99685 1/20 0.40
GSK3A P49840 2/20 0.38
GSK3B P49841 2/20 0.38
CDK2 P24941 1/20 0.38
MAPK1 P28482 1/20 0.37
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36
HDAC8 Q9BY41 1/20 0.36
KMO O15229 1/20 0.36
MAPK13 O15264 3/20 0.36
MAPK12 P53778 3/20 0.36
MAPK11 Q15759 3/20 0.36
PPIA P62937 1/20 0.36
EPHB4 P54760 1/20 0.35
BTK Q06187 2/20 0.35
GRK6 P43250 1/20 0.35
TRPV1 Q8NER1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2932911 0.88 EGFR (0.41) MAPK14MGLLGSK3AGSK3BCDK2
SCHEMBL1385324 0.86 TOP2A (0.43) MAPK14GSK3AGSK3BCDK2HDAC1
SCHEMBL2924940 0.86 GSK3A (0.41) MAPK14MGLLGSK3AGSK3BCDK2
SCHEMBL2932325 0.84 VCP (0.47) MAPK14MGLLGSK3AGSK3BCDK2
SCHEMBL1386190 0.79 CCNT1 (0.44) MAPK14CDK2MAPK13MAPK12MAPK11
SCHEMBL7529385 0.73 MAPK13 (0.48) MAPK14MAPK13MAPK12MAPK11
SCHEMBL1384875 0.73 MAPK14 (0.45) MAPK14CDK2KMOMAPK13MAPK12
SCHEMBL2928014 0.72 MAPK14 (0.46) MAPK14GSK3AGSK3BCDK2MAPK13
SCHEMBL4362141 0.72 ADORA2A (0.43) MAPK14CDK2KMOMAPK13MAPK12
SCHEMBL7222330 0.70 MAPK14 (0.52) MAPK14KMOMAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536194-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2013-09-17 US disclosed
EP-1611131-B1 PYRAZOLOPYRIDINE DERIVATES PALAU PHARMA SA (ES) 2010-09-15 EP disclosed
US-20090286983-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-11-19 US disclosed
US-20090005377-A1 Pyrazolopyridine Derivates PALAU PHARMA, S.A. (ES) 2009-01-01 US disclosed
US-7468376-B2 Pyrazolopyridine derivates PALAU PHARMA, S.A. (ES) 2008-12-23 US disclosed
US-20060167040-A1 Pyrazolopyridine derivates J. URIACH Y COMPANIA S.A. (ES) 2006-07-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060167040-A1 Pyrazolopyridine derivates MAPK1, MAP4K2, MAP4K3 MAPK14 34/4885MGLL 4731/4885GSK3A 1871/4885
US-20090286983-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MGLL 4824/4885GSK3A 2105/4885
US-20090005377-A1 Pyrazolopyridine Derivates MAPK1, MAPK4, MAP4K2 MAPK14 33/4885MGLL 4824/4885GSK3A 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.